Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 05, 2021

SELL
$105.0 - $178.37 $197,610 - $335,692
-1,882 Closed
0 $0
Q2 2021

Aug 11, 2021

SELL
$125.11 - $180.0 $7,881 - $11,340
-63 Reduced 3.24%
1,882 $333,000
Q1 2021

May 03, 2021

SELL
$126.27 - $191.71 $52,528 - $79,751
-416 Reduced 17.62%
1,945 $260,000
Q4 2020

Jan 25, 2021

SELL
$81.94 - $135.34 $6,882 - $11,368
-84 Reduced 3.44%
2,361 $320,000
Q3 2020

Oct 30, 2020

SELL
$73.3 - $89.48 $13,927 - $17,001
-190 Reduced 7.21%
2,445 $203,000
Q2 2020

Aug 10, 2020

BUY
$48.82 - $82.53 $128,640 - $217,466
2,635 New
2,635 $216,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $3.39B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Calton & Associates, Inc. Portfolio

Follow Calton & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Calton & Associates, Inc. with notifications on news.